Spirulina and polymyalgia rheumatica: IL-6, prednisolone interactions, GCA overlap, and anaemia management

PMR pathophysiology

IL-6 as the dominant driver: PMR is characterised by markedly elevated IL-6 in synovial fluid and periarticular bursae (subacromial, trochanteric). IL-6 drives the acute-phase response (elevated ESR, CRP, ferritin, fibrinogen), systemic symptoms (fatigue, fever, weight loss), and muscle pain via nociceptor sensitisation. Serum IL-6 levels correlate with disease activity and can be monitored during treatment.
NF-κB and macrophage activation: Activated CD14+ macrophages in synovial tissue produce IL-6, TNF-α, and IL-1β. NF-κB activation is central to this cytokine production. Phycocyanobilin’s NF-κB inhibition via NOX2 suppression is mechanistically aligned with reducing this inflammatory pathway. However, the immunosuppressive treatment creates the NK stimulation consideration.
GCA overlap: 15–20% of PMR patients develop GCA (large-vessel vasculitis with risk of visual loss) either concurrently or subsequently. PMR is a forme fruste of GCA in some patients — both share the IL-6-driven inflammatory pathway. If PMR symptoms are accompanied by new headache, jaw claudication, visual disturbance, or temporal artery tenderness, urgent medical assessment for GCA is required.

PMR itself is primarily macrophage and T cell-driven, with NK cells playing a minor role in the primary disease mechanism. However, PMR treatment uses prednisolone 15–25 mg/day initially, which is a genuinely immunosuppressive dose (below the 40–60 mg used in GCA but above the physiological replacement range). At 15–25 mg/day prednisolone, NK cell activity is partially suppressed. The NK stimulation concern is intermediate in PMR on standard prednisolone: lower than GCA dosing but higher than physiological hydrocortisone replacement. Discuss with prescribing physician before starting spirulina in active PMR on prednisolone.

Active PMR is associated with anaemia of chronic disease (ACD) in 40–60% of patients. IL-6 drives hepcidin synthesis, which reduces duodenal iron absorption and serum iron availability (iron trapped in reticuloendothelial system). Serum ferritin is markedly elevated in active PMR (acute-phase reactant) — it cannot be used to assess iron stores in this context. Transferrin saturation below 20% (in the presence of normal or high ferritin) confirms ACD with functional iron deficiency.
Spirulina iron (2–4 mg/5 g) contributes to dietary iron intake, though hepcidin-mediated iron restriction limits absorption during active inflammation. As prednisolone reduces IL-6 and hepcidin normalises, iron absorption (including spirulina-derived non-haem iron with vitamin C co-ingestion) improves. Monitor haemoglobin and transferrin saturation at 3-month intervals.

Bone density: Long-term prednisolone causes corticosteroid-induced osteoporosis. Spirulina calcium (~120 mg/5 g) and vitamin K contribute modestly to bone protection alongside prescribed calcium/vitamin D supplementation. Note: spirulina vitamin K (~10–15 µg/5 g) requires consistent daily dosing in patients on warfarin (sometimes used for atrial fibrillation comorbid with PMR/GCA).
Steroid-induced glucose intolerance: Prednisolone causes post-prandial hyperglycaemia in 20–30% of PMR patients. Spirulina’s adiponectin-increasing and insulin-sensitising effects may modestly attenuate prednisolone-induced glucose excursions. Monitor fasting glucose and HbA1c at 3-month intervals (standard PMR management includes this monitoring).

No pharmacokinetic interaction. CYP3A4 metabolises prednisolone; no documented spirulina CYP3A4 inhibition. NK stimulation concern at 15–25 mg/day is the primary consideration. As prednisolone tapers to 5–7.5 mg/day maintenance, NK concern diminishes.

Tocilizumab is now approved for PMR as steroid-sparing therapy (subcutaneous weekly or intravenous 4-weekly). No pharmacokinetic interaction with spirulina. NK stimulation concern on tocilizumab: IL-6 signalling modulates NK cell function, and tocilizumab reduces NK cytotoxicity as part of its action. Discuss with rheumatologist before adding spirulina to tocilizumab-based PMR management.

Low-dose methotrexate (7.5–15 mg/week) is used in relapsing PMR as steroid-sparing adjunct. No pharmacokinetic interaction with spirulina. Intermediate NK concern; discuss with rheumatologist.

Active PMR on prednisolone ≥15 mg/day: intermediate NK concern; discuss with prescribing physician; if approved, start 1–2 g/day
PMR in remission, prednisolone tapered to ≤7.5 mg/day: NK concern low; 3–5 g/day appropriate; inform physician
Monitor transferrin saturation (not ferritin alone) for iron status assessment in active PMR
Monitor HbA1c and fasting glucose every 3 months (standard PMR care includes this) — spirulina adiponectin effects may help steroid-induced glucose intolerance
Any new visual symptoms, headache, or jaw claudication requires urgent medical assessment to exclude evolving GCA